FASN and posterior cortical atrophy: In this study we evaluated TCS, which inhibits the enoyl reductase domain of FASN [8], as a repurposed drug against PCa cells and compared its activity to C75 and orlistat, two well-known FASN inhibitors whose clinical development are impeded by various pharmacological limitations (reviewed in [44]).